Biotech, in brief

The FDA approved Rasonque, also called daraxonrasib, on Wednesday for pancreatic cancer that has already spread. [1][3]

It is the first treatment to attack a genetic cause of this aggressive, highly lethal cancer. [3]

In a 500-patient trial, people on the drug lived a median 13.2 months against 6.7 months on chemotherapy. [1]

RAS is a protein that tells cells to grow, and a faulty copy drives most tumours of this kind. [1]

The drug is built to fit several faulty versions of RAS at once, not one exact version. [1]

The most common side effects listed are rash, mouth inflammation, diarrhoea, nausea, fatigue, swelling and bleeding. [1]

The label covers adults who already had one course of drug treatment, or cannot take the standard combination. [1]

Revolution Medicines set the price at $39,800 a month, about $478,000 for a year, mostly billed to insurers. [2]

More than 2,000 people have been taking it free since May under an early-access programme, and now move onto insurance. [2]

The agency cleared it 6.5 months before its own deadline, and said so in its headline and two official quotes. [1]

About 67,000 Americans are diagnosed with pancreatic cancer a year; it is 3.2% of cancer cases and far more of the deaths. [1]

It is not a cure, though some people who got it in trials have now lived for years. [2]

Median is the midpoint: half the trial did better than 13.2 months, and half did worse.

Immune-based cancer drugs have struggled in this disease [4], and that field has slowed while chasing copies of one old success. [5]

Why it matters. Watch what insurers do with a $478,000-a-year claim, and whether the 2,000 free patients transfer across without a coverage fight. [2]

Two unvaccinated Lancaster County residents died, Pennsylvania officials said Tuesday. [7][8] They are the first US measles deaths of 2026, and the state's first in 35 years. [9][10] The CDC counted 2,777 confirmed cases as of 20 August. [6]

Why it matters. Five Americans have died of measles in two years, more than in the three decades before. [7] In November, officials decide whether the country still counts as having eliminated it. [7]

New CDC data show non-medical exemptions at a record 4.2%, with about 280,000 kindergarteners lacking a measles shot. [12] Rates fell in more than half of states. [12]

Why it matters. The health secretary spent the week of the deaths arguing with a governor rather than promoting the vaccine. [11]

Worcestershire Acute Hospitals reviewed 8,500 staff after a three-month measles outbreak, and found over a quarter in patient-facing roles unvaccinated or without natural immunity. [13]

Why it matters. Three vulnerable patients, among them a pregnant woman and two transplant recipients, needed protective antibodies. [13]

Japanese regulators approved Hibsago, from GSK and Ionis, the first clearance anywhere for the drug. [14] Its makers call it a functional cure: the infection controlled rather than wiped out. [14]

Why it matters. GSK lists it among 15 drugs it expects to become top sellers, with US and other decisions still to come. [14]

Bristol Myers ended a deal worth up to $380m with Cellares, saying its automated cell-therapy factories could not make Breyanzi at commercial scale. [15] The layoffs land by 20 October. [16]

Why it matters. Living-cell treatments are still built close to one patient at a time, and that is where they keep failing. [15]

European regulators backed acoziborole, a single-dose treatment for a parasite disease that is almost always fatal untreated. [17] Trials reported success rates up to 96% at 18 months. [17]

Why it matters. The previous best option took ten days, and Sanofi has pledged to donate this one in affected countries. [17]

An independent sleuth reports more than 50 papers on cell ageing appear to list an antibody that binds a bacterial protein, not the mammalian one intended. [18]

Why it matters. Nobody has checked whether the findings still hold, and validating a reagent is slow, costly and rewarded by no one. [18]

SK Biopharma took worldwide rights to Biohaven's epilepsy drug opakalim, paying up front rather than waiting for the main trial results due later this year. [19]

Why it matters. The money is a bet on the mechanism, placed before the evidence that would price it exists. [19]

Nature Aging reported a gut bacterium that cut inflammation and extended healthspan in aged mice. [20] A Yale group blocked an immune protein called C3 and reduced age-related inflammation, also in mice. [21] A third paper built ageing clocks from 172 measures in over 100,000 Chinese adults. [22]

Why it matters. Two of the three are mouse work, and the third is a snapshot in time, not a test of anything. [22]